• Fosun Pharma (Shenzhen) won Chinese regulator clearance to start Phase I trials of FXR0906 for hypertriglyceridemia.
• FXR0906 is a liver-targeted siRNA designed to silence APOC3 mRNA, aiming to lower patients’ serum triglycerides.
• Shanghai Fosun Pharmaceutical holds exclusive China, Hong Kong, Macau rights to develop, manufacture, register, commercialize FXR0906.
• R&D spending on FXR0906 reached about RMB 71 million as of June 2026, including license fees.
• No siRNA drug for hypertriglyceridemia has been cleared for marketing in China as of July 15, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12245295), on July 15, 2026, and is solely responsible for the information contained therein.